Drug intelligence / Profile preview

Toxta

Development stage
Unknown
Lead developer
JETEMA
Modality
Recombinant Proteins and Enzymes
Administration
Intramuscular, Intradermal
01

Overview

Toxta is a botulinum toxin type A (100 units) product manufactured by the South Korean company JETEMA. It is a purified neurotoxin complex derived from *Clostridium botulinum* strain ATCC 3502. The drug functions by entering presynaptic cholinergic nerve terminals and cleaving the SNAP-25 protein, a critical component of the SNARE complex required for vesicle fusion. By blocking the release of the neurotransmitter acetylcholine, Toxta induces temporary chemo-denervation and local muscle relaxation. It is primarily indicated for aesthetic procedures, such as the temporary improvement of moderate to severe glabellar lines (dynamic facial wrinkles) in adults, and is administered via intramuscular or intradermal injection.

Brand names
Toxta
Other names
botulinum toxin type A
02

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on Toxta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toxta.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call